Biogen Inc. will launch a new Phase III study of its anti-amyloid-beta antibody aducanumab for early use to prevent or delay the clinical onset of Alzheimer’s disease. In a fourth-quarter conference call in which executives stood firm in their policy of refusing to comment on whether (or when) they might announce details of any interim or futility analysis of the heavily watched ongoing EMERGE and ENGAGE Phase III studies of aducanumab in early Alzheimer’s, observers had to settle for hints of progress in the Alzheimer’s arena.
Biogen To Launch Phase III Alzheimer’s Prevention Study
The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.
